AlphAIAlphAI — Financial news for AI agents
investing.comOCT 262 min read$AARD

H.C. Wainwright cuts Aardvark Therapeutics stock price target to $2

H.C. Wainwright reduced its price target for Aardvark Therapeutics (NASDAQ:AARD) to $2 from $4, maintaining a Neutral rating. The stock fell 63% to $1.39. The FDA lifted a clinical hold on ARD-101 for Prader-Willi Syndrome, but the company faces cash burn and clinical trial delays.

Original reporting
investing.com
Published Oct 26, 2026, 11:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 11:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$AARD
Bearish
high confidence
Mentioned
$AARD
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AARDBearishLow
01

Why it matters

The price target reduction reflects heightened risk perception, likely prompting short-term sell pressure.

02

Market read

Micro-cap biotech AARD faces near-term downside risk due to analyst downgrade amid ongoing regulatory uncertainty.

03

What to watch

Recent lift of clinical hold could be a catalyst if trial resumes successfully.

Relevance 5/10Novelty 5/10Timing: same day

Background

Aardvark Therapeutics is a clinical-stage biotech developing ARD-101 for hyperphagia in Prader-Willi Syndrome. The company has experienced multiple FDA holds and recent analyst target adjustments.

Company-level read

Ticker impact

$AARDBearishHigh confidence
Context

H.C. Wainwright lowered Aardvark Therapeutics' price target to $2 from $4, citing recent FDA actions and cash burn concerns.

Expected impact

downward pressure as investors price in lower target and clinical uncertainties

Evidence & confidence

Target cut and neutral rating signal reduced upside; recent clinical hold history adds risk.

Market effects

Sector

May weigh on other small-cap biotech stocks facing FDA scrutiny.

Regional

Limited to US biotech sector.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Potential upside if FDA fully clears ARD-101 and cash runway improves.

Key entities

  • Analyst
    H.C. Wainwright

    Equity research firm that cut the price target.

  • Regulator
    FDA

    Lifted and later placed clinical holds on AARD's drug trials.

Read at source← All news

Related articles

OCT 26
$AARDHighAI 8/10

Aardvark Therapeutics stock rating cut to Perform by Oppenheimer

Oppenheimer downgraded Aardvark Therapeutics (NASDAQ:AARD) to Perform, withdrawing its $21 price target. The stock fell 63% to $0.98, near its 52-week low, after mixed Phase 3 study results. The company plans to seek FDA feedback on a revised study design and resume clinical activities in 2027. H.C. Wainwright also lowered its price target to $2, citing ongoing challenges.

investing.com2 min
OCT 23
$AARDMedAI 8/10

FDA Lifts Clinical Hold On Aardvark's ARD-101; PWS Program Targets 2027

Aardvark Therapeutics (AARD) reported exploratory data from its terminated Phase 3 HERO trial of ARD-101 for Prader-Willi syndrome (PWS). The FDA lifted the clinical hold, and the company plans to seek guidance for a new Phase 3 trial, targeting 2027. ARD-101 showed modest efficacy in reducing hyperphagia but requires further study. AARD stock is down 48.67% year-to-date.

rttnews.com2 min
OCT 23
$AARDMedAI 8/10

Aardvark Reports Exploratory ARD-101 Data; FDA Lifts Clinical Hold

Aardvark reported exploratory data from the ARD-101 trial, showing reductions in hyperphagia scores. The FDA lifted the clinical hold on ARD-101, and the company plans to seek FDA input on a new Phase 3 trial, expecting to resume clinical activities in 2027. The trial showed modest efficacy and was generally well tolerated.

tradingview.com1 min
OCT 23
$AARDMedAI 9/10

Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials

Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials • HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory • HQ-CT scores fell by Week 2 of dose escala

SEC EDGAR 8-K2 min
OCT 23
$AARDMedAI 8/10

Aardvark reports exploratory data from terminated PWS trial

Aardvark Therapeutics (NASDAQ:AARD) reported exploratory data from its terminated Phase 3 HERO trial for ARD-101, a treatment for Prader-Willi syndrome. The trial was stopped early with 67 participants. HQ-CT scores improved during treatment but rebounded after stopping. ARD-101 was generally well-tolerated, with one serious adverse event linked to a drug interaction.

investing.com2 min
OCT 23
$AARDMedAI 8/10

A hunger-drug trial stopped early; exploratory scores fell modestly, then neared baseline after treatment ended.

Aardvark Therapeutics (AARD) halted its Phase 3 HERO trial early, reporting exploratory data showing modest reductions in HQ-CT scores for ARD-101, a hunger-suppressing drug for Prader-Willi syndrome (PWS). Scores rebounded near baseline post-treatment. The FDA lifted its clinical hold, and Aardvark plans to meet with the FDA to design a new Phase 3 trial, aiming to resume PWS clinical activities in 2027. ARD-101 was generally well-tolerated, with mild to moderate adverse events.

stocktitan.net2 min